Introduction: Effective selection of coronary lesions for revascularization is pivotal in the management of symptoms and adverse outcomes in patients with coronary artery disease (CAD). Recently, instantaneous wave-free ratio (iFR), has been proposed as a new diagnostic index for assessing the severity of coronary stenoses without the need of pharmacological vasodilation. Evidence of the effectiveness of iFR-guided revascularization is emerging and a systematic review is warranted.
Strengths and limitations of this study
• We will conduct exhaustive and systematic literature search for eligible studies in order to present a comprehensive summary of the current evidence base of the application of instantaneous wave-free ratio (iFR) in guiding coronary revascularization.
• In the current era of overdiagnosis and overtreatment, findings of our systematic reviews play an important role in informing clinical decisions in the management of patients with CAD undergoing revascularization.
• Main limitation of our systematic review is that it utilizes study-level instead of individual patient-level data. for Multivessel Evaluation (FAME) multicenter randomized study showed that, in 1005 patients with multivessel CAD, FFR-guided PCI (using drug-eluting stents (DES) and bare-metal stents (BMS)) significantly reduced the rate of the composite endpoint of death, nonfatal MI, and repeat revascularization at 1 year; 7 the favourable effects on MI as well as the combined rate of death or MI were maintained at 2-year follow-up. 8 Results of the FAME trial led to the Class IA recommendation in the European Society of Cardiology (ESC)
guidelines for FFR to be used in identifying hemodynamically significant coronary lesions when evidence of ischaemia is unavailable. 9,10 Using a criterion of FFR ≤0.80 to indicate functionally significant stenoses, the subsequent FAME II trial further demonstrated that FFR-guided PCI (using DES) reduced the need for urgent revascularization amongst 1220 patients with stable CAD at 2-year follow up. 11, 12 This body of evidence prompted the inclusion of FFR measurement as an indication in the appropriate use criteria (AUC) for coronary revascularization in patients with acute coronary syndomes (ACS) as well as patients with stable ischemic heart disease (IHD).
13,14
Despite the proven clinical and economic benefits, 15 FFR-guided strategy is not without limitations. Firstly, the fundamental assumption of FFR is that there is linearity between coronary pressure and flow during maximal hyperemia, for which a static, stable intracoronary resistance is required; however, both assumptions do not exist in real life and represent potential errors in the measurement of FFR. 16 In the context of clinical practice and patient-relevant outcomes, the need of pharmacological maximal vasodilatation for FFR-guided revascularization poses as another limitation. The most frequently used vasodilator and current gold standard to induce hyperemia is intravenous infusion of adenosine. 9,10 However, adenosine is associated with substantial adverse effects and patient discomfort such as dyspnea, chest pain, headache, and it is contraindicated in patients with documented allergy to adenosine or severe asthma. 17 Therefore, in the real-world settings, the adoption of FFR was found to be low. 18 Consequently, researchers and clinicians proposed an alternative pressure-derived index that does not require the administration of vasodilators and where measurements can be obtained during naturally constant and minimal intracoronary resistance: the instantaneous wave-free ratio (iFR). 18 The breakthrough ADenosine
Vasodilator Independent Stenosis Evaluationis (ADVISE) study illustrated the existence of a wave-free diastolic window in the cardiac cycle when coronary resistance is naturally stable and minimal (starting 112±26 ms after the onset of diastole), and the iFR measured during this wave-free period was found to be closely correlated with the FFR. 19 Subsequent studies further demonstrated good diagnostic accuracy of iFR and high level of diagnostic agreement with FFR; optimal iFR cut-off value of ≤0.89 to 0.90 was found to be the best match to FFR of ≤0.80 and iFR was recognized as an vasodilator-free alternative to FFR. [20] [21] [22] However, conflicting results also emerged, with studies showing that iFR correlated weakly with FFR and provided a biased estimate of FFR on average as well as uncertain estimate of FFR in certain individual cases, which collectively limit the widespread application of iFR and led to one group of study authors to advise against the use of iFR for clinical decision making in CAD patients.
23-25
The ongoing debate circulating the role of iFR as a viable guidance strategy for revascularization is further fuelled by the lack of outcome-based randomized controlled trials (RCTs) to investigate the clinical efficacy and safety associated with the use of iFR-guided 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
OBJECTIVES
This is a protocol for a systematic review to evaluate the efficacy and safety of iFR guidance in CAD patients undergoing coronary revascularization.
METHODS AND ANALYSIS
Our systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement.
26

Eligibility criteria
Types of studies
Randomised controlled trials (RCTs) and controlled observational studies (including cohort and case-control studies) will be included. No restrictions on language or publication status will be imposed.
Types of participants
Patients with CAD (stable or ACS) undergoing coronary revascularization, including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) will be included.
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Types of interventions and comparators
Coronary revascularisation guided by instantaneous wave-free ratio (iFR), defined as the resting pressure gradient across a coronary lesion during the diastolic "wave-free" period. The cut-off value of iFR will be as defined by the included studies. Comparators will include other diagnostic techniques for coronary revascularization, such as coronary angiography, FFR, intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
Types of outcome measures
Our primary outcomes of interest include: all-cause mortality, cardiovascular mortality, myocardial infarction (fatal and nonfatal), unplanned revascularisation. Secondary outcomes are target lesion revascularisation, stent thrombosis, coronary stenosis and adverse effects (both patient-and physician-reported).
Search methods
We will search the following electronic bibliographic databases: MEDLINE, EMBASE, The
Cochrane Library (Cochrane Database of Systematic Reviews (CDSR), Cochrane Central
Register of Controlled Trials (CENTRAL)), and University of York Centre for Reviews and Dissemination Health Technology Assessment (HTA) Database, using search terms that are related to the intervention ("instantaneous wave-free ratio" OR "iFR"). Trial registers e.g.
Clinicaltrials.gov will be screened for ongoing and unpublished studies. In addition, we will review safety reports released by the regulatory authorities (US Food and Drug 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   10 Administration and European Medicines Agency). Reference lists of relevant narrative reviews and included trials will also be reviewed for additional information.
Data collection and synthesis
Study selection
Two independent authors (JSWK, SYL) will screen all titles and abstracts identified from the systematic literature search; potentially eligible records will be further assessed by obtaining their full-text articles and these will again be screened by the same independent authors.
Discrepancies will be resolved by consensus or by consulting a third author (CMY). A PRISMA flow diagram will be used to document our study selection process.
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Data extraction
A pre-standardized data extraction form will be used to extract data from the included studies.
We will extract the following information: study design; type of study population (demographics and baseline characteristics); type of study intervention and comparator(s); recruitment and study completion rates; outcomes and times of measurement; information for assessment of the risk of bias. Data will be extracted by two authors independently (CZ, CX), and any disagreement will be resolved through discussion or by consultation with a third author (JSWK). In case of missing data, we will attempt to retrieve them by contacting the study investigators. 
Assessment of risk of bias in included studies
Data synthesis
We will use the Review Manager software (version 5.3) for data analysis. Data from randomized controlled trials and observational studies will be meta-analysed separately and presented as forest plots. Risk ratios (RRs) and the corresponding 95% confidence intervals (Cis) will be calculated for dichotomous (binary) data; for continuous outcomes, weighted mean differences (WMDs) will be used.
Statistical heterogeneity will be explored by the chi-squared (Chi 2 ) test and quantified by the I 2 statistic, with P value of <0.10 for the Chi 2 test and I 2 of ≥50% will indicate substantial statistical heterogeneity. 27 In the case of substantial heterogeneity, we will employ a Should quantitative synthesis be deemed inappropriate, we will present our findings of all outcomes as narrative summaries.
ETHICS AND DISSEMINATION
Ethical approval is not required for this systematic review since data involved will be anonymous and do not concern the privacy of individual patients. Results of this systematic review will be disseminated in a peer-reviewed journal and conference proceedings.
DISCUSSION
Our systematic review will provide useful insights and shed light on the ongoing debate of the application of iFR, a new non-invasive diagnostic index, in selecting patients for coronary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 8,9
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 9
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 9 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 10 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
10
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 10 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Contributors: JSWK and CMY conceived the idea of the study. JSWK wrote the draft of the protocol and SYL, HC, WJG, CZ, XTZ and CMY revised it. JSWK and SYL will search and select eligible studies; JSWK and CZ will extract data; HC and WJG will assess risk of bias, and XTZ will perform data synthesis. JSWK and CMY act as guarantors of the protocol. All authors approved the publication of the protocol.
Funding sources: None. 
Methods and analysis:
This is a protocol for a systematic review of randomized controlled trials (RCTs) and controlled observational studies. Electronic sources including MEDLINE, EMBASE, Cochrane databases and ClinicalTrials.gov will be searched for potentially eligible studies investigating the effects of iFR-guided strategy in patients undergoing coronary revascularization. Studies will be selected against transparent eligibility criteria and data will be extracted using a pre-standardized data collection form by two independent authors. Risk of bias in included studies and overall quality of evidence will be assessed using validated methodological tools. Meta-analysis will be performed using the Review Manager software.
Our systematic review will be performed according to the guidance from the Cochrane
Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement.
Ethics and dissemination:
Ethics approval is not required. Results of the systematic review will be disseminated as conference proceedings and peer-reviewed journal publication.
Trial registration number: This protocol is registered in the International Prospective
Register of Systematic Reviews (PROSPERO), registration number CRD42017065460. 
Strengths and limitations of this study
• We will conduct an exhaustive and systematic literature search for eligible studies in order to present a comprehensive summary of the current evidence base of the application of instantaneous "wave-free" ratio (iFR) in guiding coronary revascularization.
• In the current era of overdiagnosis and overtreatment, findings of systematic reviews play an important role in informing clinical decisions in the management of patients with CAD undergoing revascularization.
• Main limitation of our systematic review is that it utilizes study-level instead of individual patient-level data. between the diagnostic lesion severity and post-mortem findings. 3 Consequently, the concept of myocardial fractional flow reserve (FFR) was introduced as a new physiological index of functional severity of coronary stenoses and for determining ischemia-producing coronary lesions for revascularization. 4, 5 FFR is defined as the pressure distal to a stenosis divided by the pressure before the stenosis during coronary hyperemia and is derived from the ratio of the mean distal artery pressure to the aortic pressure during maximal hyperemia induced by pharmacological vasodilators such as adenosine. 5, 6 The landmark Fractional Flow Reserve versus Angiography adenosine. 9,10 However, adenosine is associated with substantial adverse effects and patient discomfort such as dyspnea, chest pain, headache, and it is contraindicated in patients with documented allergy to adenosine or severe asthma. 17 Therefore, in the real-world settings, the adoption of FFR was found to be low. 18 Consequently, researchers and clinicians proposed an alternative pressure-derived index that does not require the administration of vasodilators and where measurements can be obtained during naturally constant and minimal intracoronary resistance: the instantaneous "wave-free" ratio (iFR). 18 The breakthrough ADenosine
Vasodilator Independent Stenosis Evaluationis (ADVISE) study illustrated the existence of a "wave-free" diastolic window in the cardiac cycle when coronary resistance is naturally stable and minimal (starting 112±26 ms after the onset of diastole), and the iFR measured during this showing that iFR at either ≤0.80 or ≤0.83 correlated poorly with FFR of ≤0.80, 22 which collectively limit the widespread application of iFR and led to the VERIFY study authors to advise against the use of iFR for clinical decision making in CAD patients. 22 However, it is worth highlighting that, in a subsequent independent core laboratory-based retrospective analysis of VERIFY study data, a better correlation with FFR without systematic bias was 
OBJECTIVES
METHODS AND ANALYSIS
Our systematic review will be performed according to the Cochrane Handbook for Systematic
Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Statement.
24,25
Eligibility criteria
Types of studies
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Types of participants
Types of interventions and comparators
Coronary revascularisation guided by instantaneous "wave-free" ratio (iFR), defined as the resting pressure gradient across a coronary lesion during the diastolic "wave-free" period. The cut-off value of iFR will be as defined by the included studies. Comparators will include other diagnostic techniques for coronary revascularization, such as coronary angiography, FFR, intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
Types of outcome measures
Search methods
Cochrane Library (Cochrane Database of Systematic Reviews (CDSR), Cochrane Central 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (table 1 ) and the search strategy will be adapted for use in each database. Trial registers e.g. Clinicaltrials.gov will be screened for ongoing and unpublished studies. In addition, we will review safety reports released by the regulatory authorities (US Food and Drug Administration and European Medicines Agency).
Reference lists of relevant narrative reviews and included trials will also be reviewed for additional information.
Data collection and synthesis
Study selection
Two independent authors (JSWK, SYL) will screen all titles and abstracts identified from the systematic literature search; potentially eligible records will be further assessed by obtaining their full-text articles and these will again be screened by the same independent authors. Discrepancies will be resolved by consensus or by consulting a third author (CMY). A PRISMA flow diagram will be used to document our study selection process.
25
Data extraction
We will extract the following information: study design; type of study population (demographics and baseline characteristics); type of study intervention and comparator(s); recruitment and study completion rates; outcomes and times of measurement; information for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 , and any disagreement will be resolved through discussion or by consultation with a third author (CMY). In case of missing data, we will attempt to retrieve them by contacting the study investigators.
Assessment of risk of bias in included studies
For randomised controlled trials (RCTs), we will use the Cochrane Collaboration's tool for assessing risk of bias, 24 focusing on the following six domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. Risk of bias in included studies will be assessed by two independent authors (HC, WJG) and disagreements will be resolved by discussion or by consulting a third author (JSWK) where necessary. For 
Data synthesis
We will use the Review Manager software (version 5.3) for data analysis. Data from randomized controlled trials and observational studies will be meta-analysed separately and 27 In the case of substantial heterogeneity, we will employ a random-effects model for performing meta-analysis. In other cases, a fixed effect model will be used. Publication bias will be investigated if the number of included studies exceeds 10, using funnel plots for visual symmetry as well as the Egger's test.
24,27
We plan to perform the following subgroup analyses if data are available and sufficient:
cut-off value of iFR, types of CAD patients (stable, ACS), types of revascularization (PCI or CABG), types of control interventions (FFR, IVUS, CTO). We will also conduct sensitivity analysis by the level of risk of bias in included studies.
Summary of findings tables will be used to illustrate the results of our assessment of the quality of evidence for each outcome according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework, which considers the overall risk of bias, inconsistency, indirectness, imprecision and publication bias.
28
Should quantitative synthesis be deemed inappropriate, we will present our findings of all outcomes as narrative summaries.
ETHICS AND DISSEMINATION
DISCUSSION
The concept of FFR has been hailed as a pivotal paradigm shift in the management of CAD since it was first introduced in the 1990s by Pijls and colleagues, 29, 30 and its impact in the era of PCI has been illustrated over the years in the landmark DEFER, 31 FAME and FAME 2 trials. 7, 8, 11, 12 Moreover, vasodilators other than adenosine, e.g. intravenous regadenoson, a specific A 2A adenosine receptor agonist, 32 have been investigated as viable options for FFR measurement with better safety profiles. Nevertheless, iFR poses as an attractive drug-free alternative for which investigators and researchers hope would increase adoption of coronary physiology assessment in the real world using simpler, less expensive measurement methods with better patient tolerance. 33, 34 The latter is especially important in clinical decision-making and long-term management and prognosis of CAD. The question of whether iFR could be a feasible "FFR-like" index for assessing stenosis severity in CAD has been explored in numerous observational studies and randomised trials and a comprehensive systematic review assessing the currently available evidence is thus warranted.
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METHODS
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